ClinicalTrials.gg
RecruitingNCT04982653Updated Nov 12, 2026

Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy

A Phase 2 interventional study of Quality-of-Life Assessment and Surgical Procedure in Liver and Intrahepatic Bile Duct Neoplasm, Metastatic Malignant Neoplasm in the Liver and Primary Malignant Liver Neoplasm, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center — 6 open to participants now, 15 under way, none of them phase 3. Carcinoma, Hepatocellular · M.D. Anderson Cancer Center.

Planned enrollment
5th of 34
140 · median 39
Started
2022
with 5 others
Phase 2
12 of 36
1 open now
Primary completion
2027-02
later than 5 of 14 live
Registered
25th of 36
by date

Among the 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center, this one is the 5th largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2022, is one of 12 in phase 2, reaches primary completion later than 5 of the 14 other live ones, and was the 25th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

6 of the 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Carcinoma, Hepatocellular by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This clinical trial compares two different kinds of surgical closing techniques, short stitch suture or traditional suture, in patients who are having liver tumor surgery. This study may help researchers learn if one technique can lower the chances of developing a hole in the wall of the abdomen (an abdominal hernia) at the incision site better than the other.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess whether small bites abdominal wall closure reduces the risk of developing incisional hernia following liver surgery.

SECONDARY OBJECTIVES:

I. To compare short-term perioperative outcomes between small bites and typical fascial closure technique.

II. To assess the hernia incidence rate of short stich versus (vs.) standard closure in subgroups of patients with inverted-L or midline incisions.

III. To assess the hernia incidence rate of Kawaguchi-Gayet hepatectomy complexity classifications I/II vs. III (hernia rate by extent of hepatectomy).

IV. To assess the hernia incidence rate of preoperative chemotherapy or no preoperative chemotherapy (hernia rate by exposure to preoperative chemotherapy).

V. To assess impact of small bites abdominal wall closure on health care quality of life following liver surgery.

VI. To assess safety of small tissue bites fascial closure suture technique versus conventional fascial closure following hepatectomy.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (INTERVENTION): Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.

ARM II (CONTROL): Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.

After completion of study, patients are followed up at 1-4 weeks, and then at 3, 6, and 12 months.

03

Conditions studied

  • Liver and Intrahepatic Bile Duct Neoplasm
  • Metastatic Malignant Neoplasm in the Liver
  • Primary Malignant Liver Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing hepatectomy for malignant diagnosis (primary or secondary) from 5/1/2021 through 11/1/2024 will be eligible for inclusion in this study
  • Elective surgery
  • Age >= 18
  • Planned midline laparotomy incision or inverted-L incision

Exclusion criteria

Exclusion Criteria:

  • Pre-existing abdominal hernia
  • History of mesh placement at prior laparotomy
  • Pregnant women
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Arm I (hepatectomy using small bites fascial closure)

    Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.

    Other: Quality-of-Life Assessment · Procedure: Surgical Procedure

  • Active comparator
    Arm II (hepatectomy using conventional fascial method)

    Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.

    Other: Quality-of-Life Assessment · Procedure: Surgical Procedure

Interventions

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • ProcedureSurgical Procedure

    Undergo hepatectomy using small bites fascial method for abdominal wall closure

    Also known as: Operation, Surgery, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery

  • ProcedureSurgical Procedure

    Undergo hepatectomy using conventional fascial method for abdominal wall closure

    Also known as: Operation, Surgery, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery

06

What researchers measure

Primary outcomes

  1. Radiographic incidence rate of incisional hernia

    Definition of incisional hernia will be based on the European Hernia Society: Any abdominal wall gap with or without a bulge in the area of a postoperative scar perceptible or palpable by clinical examination or imaging. Assessment of the primary outcome will occur at 3, 6, and 12 months with a computed tomography scan/magnetic resonance imaging. Scans will be read and assessed for incisional hernia by 3 independent assessors blinded to the allocation. A correlation coefficient will be determined for their assessments. The cumulative incidence rate of incisional hernia at 12 months will be estimated, along with the 95% confidence interval.

    Time frame: Up to 12 months after surgery

Secondary outcomes

  1. Surgical site infection

    Time frame: Up to 90 days after surgery

  2. Surgical site occurrence

    Time frame: Up to 90 days after surgery

  3. Surgical site occurrence requiring procedural intervention

    Time frame: Up to 90 days after surgery

  4. Postoperative complications

    Post-operative infection, complication or pain will be assessed using Chi-squared test or Fisher's exact test.

    Time frame: Up to 90 days after surgery

  5. Need for reoperation

    Time frame: Up to 90 days after surgery

  6. Need for reoperation secondary to complication of abdominal closure

    Time frame: Up to 90 days after surgery

  7. Length of hospital stay (postoperatively)

    Will be compared between the two arms using two-sample t-test or Wilcoxon rank sum test.

    Time frame: Up to 90 days after surgery

  8. Any readmission related to hernia repair

    Time frame: Up to 30 days after surgery

  9. Health-related quality of life assessment

    Will use linear mixed effect modeling to assess the effects of time, arm as well as the interaction between arm and time.

    Time frame: Up to 12 months after surgery

  10. Incidence of adverse events (AEs)

    Will be summarized using descriptive statistics (frequency, percentage) by arm, AE type, severity and attribution.

    Time frame: Up to 90 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 60 months is above that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2021
First posted
Jul 29, 2021
StartActual
Jan 4, 2022
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04982653
Responsible party
Sponsor
First posted
Jul 29, 2021
Start date
Jan 4, 2022
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Timothy E Newhook, MD
Contact
TNewhook@mdanderson.org
713-792-6940
Timothy E Newhook, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion